Public offering

Proposed Dual-Listing on Nasdaq

Friday, May 14, 2021 - 7:00am

b'GAITHERSBURG, Md., May 14, 2021 /PRNewswire/ --MaxCyte, Inc. (LSE: MXCT, MXCL, MXCN) ("MaxCyte" or the "Company"), a leading provider of platform technologies for cell engineering, today announces that it has confidentially submitted a draft registration statement on Form S-1 with the Securities and Exchange Commission (the "SEC") relating to a proposed dual-listing and public offering of shares of common stock on the Nasdaq Stock Market (the "Offering").\nThe number of securities to be offered and the price for the proposed Offering have not yet been determined.

Key Points: 
  • b'GAITHERSBURG, Md., May 14, 2021 /PRNewswire/ --MaxCyte, Inc. (LSE: MXCT, MXCL, MXCN) ("MaxCyte" or the "Company"), a leading provider of platform technologies for cell engineering, today announces that it has confidentially submitted a draft registration statement on Form S-1 with the Securities and Exchange Commission (the "SEC") relating to a proposed dual-listing and public offering of shares of common stock on the Nasdaq Stock Market (the "Offering").\nThe number of securities to be offered and the price for the proposed Offering have not yet been determined.
  • The Offering is expected to commence after the SEC completes its review process, subject to market and other conditions, and shareholders and potential investors should note that the proposed Offering may or may not proceed.\nThis press release is being made pursuant to, and in accordance with, Rule 135 under the Securities Act of 1933, as amended (the "Securities Act").
  • MaxCyte\'s existing customer base ranges from large biopharmaceutical companies, including all of the top 10, and 20 of the top 25, pharmaceutical companies based on 2020 global revenue, to hundreds of biotechnology companies and academic centers focused on translational research.
  • MaxCyte has granted 12 strategic platform licences to commercial cell therapy developers.

Praxis Precision Medicines Prices Public Offering of Common Stock

Friday, May 14, 2021 - 3:39am

b'CAMBRIDGE, Mass., May 13, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders (CNS) characterized by neuronal imbalance, today announced that it has priced an underwritten public offering of 5,000,000 shares of its common stock at a public offering price of $18.25 per share.

Key Points: 
  • b'CAMBRIDGE, Mass., May 13, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders (CNS) characterized by neuronal imbalance, today announced that it has priced an underwritten public offering of 5,000,000 shares of its common stock at a public offering price of $18.25 per share.
  • The gross proceeds to Praxis from the offering are expected to be approximately $91.25 million, before deducting the underwriting discounts and commissions and other offering expenses.
  • Praxis has granted the underwriters a 30-day option to purchase up to an additional 750,000 shares of its common stock.\nAll shares in the offering are to be sold by Praxis.
  • The public offering is being made by Praxis only by means of a prospectus relating to the offering.

Vera Therapeutics Announces Pricing of Initial Public Offering

Friday, May 14, 2021 - 1:52am

b'SOUTH SAN FRANCISCO, Calif., May 13, 2021 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (\xe2\x80\x9cVera\xe2\x80\x9d), a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the pricing of its initial public offering of 4,350,000 shares of its Class A common stock at a price to the public of $11.00 per share.

Key Points: 
  • b'SOUTH SAN FRANCISCO, Calif., May 13, 2021 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (\xe2\x80\x9cVera\xe2\x80\x9d), a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the pricing of its initial public offering of 4,350,000 shares of its Class A common stock at a price to the public of $11.00 per share.
  • The gross proceeds to Vera from the offering, before deducting the underwriting discounts and commissions and offering expenses, are expected to be $47.85 million.
  • All of the shares are being offered by Vera.
  • This offering is being made only by means of a written prospectus, forming a part of the effective registration statement.

Digital Brands Group, Inc. Announces Pricing of $10.0 Million Initial Public Offering and Nasdaq Listing

Friday, May 14, 2021 - 1:58am

In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 361,445 shares and 361,445 warrants at the public offering price less the underwriting discounts and commissions.

Key Points: 
  • In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 361,445 shares and 361,445 warrants at the public offering price less the underwriting discounts and commissions.
  • Manatt, Phelps & Phillips, LLP represented Digital Brands and Nelson Mullins Riley & Scarborough LLP acted for Kingswood.\nThe Securities and Exchange Commission ("SEC") declared effective a registration statement on Form S-1 (File No.
  • The Company has strategically expanded into an omnichannel brand offering these styles and content not only on-line but at selected wholesale and retail storefronts.
  • No assurance can be given that the offering will be completed on the terms described, or at all.

SAVE FOODS, INC. ANNOUNCES PRICING OF $12 MILLION PUBLIC OFFERING AND NASDAQ LISTING

Thursday, May 13, 2021 - 10:50pm

Save Foods has granted the underwriter a 45-day option to purchase up to 163,636 additional shares of Common Stock to cover over-allotments, if any, at the public offering price, less the underwriting discounts and commissions.

Key Points: 
  • Save Foods has granted the underwriter a 45-day option to purchase up to 163,636 additional shares of Common Stock to cover over-allotments, if any, at the public offering price, less the underwriting discounts and commissions.
  • The Offering is expected to close May 18, 2021, subject to satisfaction of customary closing conditions.
  • A final prospectus relating to this offering will be filed with the Securities and Exchange Commission.
  • Because such statements deal with future events and are based on Save Foods\xe2\x80\x99 current expectations, they are subject to various risks and uncertainties.

Decibel Therapeutics Reports First Quarter 2021 Financial Results and Corporate Update

Thursday, May 13, 2021 - 10:05pm

In early 2021, we announced encouraging preclinical results on our lead gene therapy program, DB-OTO, for the treatment of people with otoferlin deficiency.

Key Points: 
  • In early 2021, we announced encouraging preclinical results on our lead gene therapy program, DB-OTO, for the treatment of people with otoferlin deficiency.
  • We also established a critical cGMP manufacturing and development relationship with Catalent,\xe2\x80\x9d said Laurence Reid, Ph.D., Chief Executive Officer of Decibel.
  • Additionally, Decibel completed its Initial Public Offering (IPO) of 7,662,000 shares of common stock at a public offering price of $18.00 per share.
  • However, while Decibel may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so.

Eloxx Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock

Thursday, May 13, 2021 - 9:01pm

b"WALTHAM, Mass., May 13, 2021 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (the \xe2\x80\x9cCompany\xe2\x80\x9d) (Nasdaq: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announced that it has commenced an underwritten public offering of shares of its common stock.

Key Points: 
  • b"WALTHAM, Mass., May 13, 2021 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (the \xe2\x80\x9cCompany\xe2\x80\x9d) (Nasdaq: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announced that it has commenced an underwritten public offering of shares of its common stock.
  • In addition, the Company expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock at the public offering price, less underwriting discounts and commissions.\nB.
  • Riley Securities, Inc. is acting as sole-book running manager for the offering.
  • The final terms of the offering will be disclosed in a final prospectus supplement to be filed with the SEC.

Monaker Group Announces Proposed Public Offering of Common Stock

Thursday, May 13, 2021 - 9:05pm

b'Sunrise, FL, May 13, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Monaker Group, Inc. (NASDAQ: MKGI), a technology solutions company focused on building a digital business ecosystem that caters to and ties together digital advertisers, consumers, video gamers and travelers, today announced that it has commenced an underwritten public offering of its common stock.

Key Points: 
  • b'Sunrise, FL, May 13, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Monaker Group, Inc. (NASDAQ: MKGI), a technology solutions company focused on building a digital business ecosystem that caters to and ties together digital advertisers, consumers, video gamers and travelers, today announced that it has commenced an underwritten public offering of its common stock.
  • All of the shares in the offering are being offered by Monaker.
  • In addition, Monaker expects to grant the underwriters a 45-day option to purchase up to an additional 15% of shares of its common stock on the same terms and conditions.
  • A preliminary prospectus supplement and the accompanying prospectus relating to and describing the terms of the offering has been filed with the SEC.

Recro Announces Pricing of $30.0 Million Public Offering of Common Stock

Wednesday, May 12, 2021 - 1:30pm

Gross proceeds, before underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $30.0 million.

Key Points: 
  • Gross proceeds, before underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $30.0 million.
  • In addition, Recro has granted the underwriters a 30-day option to purchase up to 1,999,999 additional shares of its common stock at the public offering price, less underwriting discounts and commissions.
  • Recro does not have immediate arrangements, commitments or understandings regarding any future acquisitions.\nWilliam Blair & Company, L.L.C.
  • These statements, among other things, the Company\xe2\x80\x99s expectations regarding the completion of the public offering, the Company\xe2\x80\x99s use of proceeds from the proposed offering, and other statements.

SnapAV Announces Confidential Submission of Draft Registration Statement for Proposed Initial Public Offering

Wednesday, May 12, 2021 - 2:00pm

b'Wirepath Home Systems, LLC dba SnapAV, a leader in the connected home technology market, today announces that its parent company has confidentially submitted a draft registration statement on Form S-1 with the Securities and Exchange Commission (the \xe2\x80\x9cSEC\xe2\x80\x9d) relating to the proposed initial public offering of the company\xe2\x80\x99s common stock.

Key Points: 
  • b'Wirepath Home Systems, LLC dba SnapAV, a leader in the connected home technology market, today announces that its parent company has confidentially submitted a draft registration statement on Form S-1 with the Securities and Exchange Commission (the \xe2\x80\x9cSEC\xe2\x80\x9d) relating to the proposed initial public offering of the company\xe2\x80\x99s common stock.
  • The number of shares to be offered and the price range for the proposed offering have not yet been determined.
  • The initial public offering is expected to commence after the SEC completes its review process, subject to market and other conditions.\nThis news release is being made pursuant to and in accordance with Rule 135 under the Securities Act of 1933, as amended, and does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210512005062/en/\n'